STOCK TITAN

[SCHEDULE 13G/A] Dianthus Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. Schedule 13G/A reports that Point72-related entities and Steven A. Cohen collectively have shared voting and dispositive power over 1,445,825 shares of Dianthus common stock, representing 4.5% of the class as of the close of business on June 30, 2025. The filing states the shares are held by an investment fund managed by Point72 Asset Management; Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management and Mr. Cohen controls both entities. Each reporting person reports 0 sole voting and 0 sole dispositive power, with all reported power listed as shared. The statement clarifies the filing should not be construed as admission of beneficial ownership for purposes of Section 13.

Dianthus Therapeutics, Inc. - Nel modulo Schedule 13G/A si segnala che entità collegate a Point72 e Steven A. Cohen detengono congiuntamente il potere di voto e dispositivi su 1.445.825 azioni ordinarie di Dianthus, pari a il 4,5% della categoria alla chiusura delle contrattazioni del 30 giugno 2025. La dichiarazione indica che le azioni sono in capo a un fondo d’investimento gestito da Point72 Asset Management; Point72 Capital Advisors, Inc. è la società generale di Point72 Asset Management e il sig. Cohen esercita controllo su entrambe le entità. Ciascun dichiarante riporta 0 voti esclusivi e 0 poteri dispositivi esclusivi, con tutti i poteri indicati come condivisi. Si precisa che la comunicazione non costituisce ammissione di titolarità effettiva ai sensi della Sezione 13.

Dianthus Therapeutics, Inc. - El Schedule 13G/A informa que entidades relacionadas con Point72 y Steven A. Cohen comparten colectivamente el poder de voto y dispositivo sobre 1.445.825 acciones comunes de Dianthus, representando el 4,5% de la clase al cierre de mercado del 30 de junio de 2025. La presentación indica que las acciones están en un fondo gestionado por Point72 Asset Management; Point72 Capital Advisors, Inc. es la sociedad gestora general de Point72 Asset Management y el Sr. Cohen controla ambas entidades. Cada declarante informa 0 voto exclusivo y 0 poder dispositivo exclusivo, quedando todo el poder reportado como compartido. Se aclara que la presentación no debe interpretarse como una admisión de propiedad beneficiaria a efectos de la Sección 13.

Dianthus Therapeutics, Inc. - Schedule 13G/A 보고서에 따르면 Point72 관련 법인들과 스티븐 A. 코헨이 함께 1,445,825주의 Dianthus 보통주에 대한 의결권 및 처분권을 공동으로 보유하고 있으며, 이는 2025년 6월 30일 장 마감 기준 총 발행주식의 4.5%에 해당합니다. 제출서에는 해당 주식이 Point72 Asset Management가 운용하는 투자펀드에 속한다고 기재되어 있으며, Point72 Capital Advisors, Inc.는 Point72 Asset Management의 제너럴 파트너이고 코헨 씨가 두 법인을 통제한다고 명시되어 있습니다. 각 보고자는 단독 의결권 0단독 처분권 0을 보고했으며, 보고된 모든 권한은 공동 권한으로 표기되어 있습니다. 이 제출은 섹션 13의 목적상 실질적 소유권의 인정으로 해석되어서는 안 된다고 명시합니다.

Dianthus Therapeutics, Inc. - Le Schedule 13G/A indique que des entités liées à Point72 et Steven A. Cohen détiennent conjointement le pouvoir de vote et de disposition sur 1 445 825 actions ordinaires de Dianthus, soit 4,5 % de la catégorie à la clôture des marchés le 30 juin 2025. Le dépôt précise que les actions sont détenues par un fonds d’investissement géré par Point72 Asset Management ; Point72 Capital Advisors, Inc. est le partenaire général de Point72 Asset Management et M. Cohen contrôle les deux entités. Chaque déclarant signale 0 pouvoir de vote exclusif et 0 pouvoir de disposition exclusif, tous les pouvoirs étant déclarés comme partagés. Il est précisé que cette déclaration ne doit pas être interprétée comme une reconnaissance d’une propriété bénéficiaire au sens de la Section 13.

Dianthus Therapeutics, Inc. - In der Schedule 13G/A wird berichtet, dass Point72-nahe Einheiten und Steven A. Cohen zusammen die Stimm- und Verfügungsgewalt über 1.445.825 Aktien der Dianthus-Stammaktien innehaben, was zum Börsenschluss am 30. Juni 2025 4,5 % der Klasse entspricht. Die Einreichung gibt an, dass die Aktien von einem von Point72 Asset Management verwalteten Investmentfonds gehalten werden; Point72 Capital Advisors, Inc. ist der Generalpartner von Point72 Asset Management und Herr Cohen übt Kontrolle über beide Einheiten aus. Jeder Meldende gibt 0 alleinige Stimmrechte und 0 alleinige Verfügungsrechte an; alle gemeldeten Rechte sind als gemeinsam ausgewiesen. Es wird klargestellt, dass die Meldung nicht als Anerkennung einer wirtschaftlichen Eigentümerschaft im Sinne von Abschnitt 13 zu verstehen ist.

Positive
  • Transparent disclosure of holdings: 1,445,825 shares reported with specific shared voting and dispositive power
  • Clear chain of control identified: Point72 Asset Management manages the fund, Point72 Capital Advisors is general partner, and Steven A. Cohen controls the entities
  • Position below 5% threshold (4.5%), consistent with passive reporting under Schedule 13G/A
Negative
  • None.

Insights

TL;DR: Point72 reports a 4.5% shared stake in Dianthus, a non-controlling position below the 5% threshold.

Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen disclose shared voting and dispositive power over 1,445,825 shares as of June 30, 2025. The filing shows no sole voting or dispositive power and explicitly notes the position is not intended to influence control of the issuer. Because the stake is under 5%, this is a routine Section 13G disclosure reflecting passive or qualifying investor status rather than an active acquisition or control intent. Investors should view this as a transparency filing rather than a material change to corporate control.

TL;DR: Disclosure is complete and consistent with passive ownership reporting; ownership structure shows common control through Point72 entities.

The document identifies the reporting chain: Point72 Asset Management manages the fund owning the shares, Point72 Capital Advisors is the general partner, and Steven A. Cohen controls those entities. The certification clarifies the securities were not acquired to change control. All signatures are executed by an authorized person. From a governance perspective, the filing documents influence via shared powers but does not indicate an active control campaign.

Dianthus Therapeutics, Inc. - Nel modulo Schedule 13G/A si segnala che entità collegate a Point72 e Steven A. Cohen detengono congiuntamente il potere di voto e dispositivi su 1.445.825 azioni ordinarie di Dianthus, pari a il 4,5% della categoria alla chiusura delle contrattazioni del 30 giugno 2025. La dichiarazione indica che le azioni sono in capo a un fondo d’investimento gestito da Point72 Asset Management; Point72 Capital Advisors, Inc. è la società generale di Point72 Asset Management e il sig. Cohen esercita controllo su entrambe le entità. Ciascun dichiarante riporta 0 voti esclusivi e 0 poteri dispositivi esclusivi, con tutti i poteri indicati come condivisi. Si precisa che la comunicazione non costituisce ammissione di titolarità effettiva ai sensi della Sezione 13.

Dianthus Therapeutics, Inc. - El Schedule 13G/A informa que entidades relacionadas con Point72 y Steven A. Cohen comparten colectivamente el poder de voto y dispositivo sobre 1.445.825 acciones comunes de Dianthus, representando el 4,5% de la clase al cierre de mercado del 30 de junio de 2025. La presentación indica que las acciones están en un fondo gestionado por Point72 Asset Management; Point72 Capital Advisors, Inc. es la sociedad gestora general de Point72 Asset Management y el Sr. Cohen controla ambas entidades. Cada declarante informa 0 voto exclusivo y 0 poder dispositivo exclusivo, quedando todo el poder reportado como compartido. Se aclara que la presentación no debe interpretarse como una admisión de propiedad beneficiaria a efectos de la Sección 13.

Dianthus Therapeutics, Inc. - Schedule 13G/A 보고서에 따르면 Point72 관련 법인들과 스티븐 A. 코헨이 함께 1,445,825주의 Dianthus 보통주에 대한 의결권 및 처분권을 공동으로 보유하고 있으며, 이는 2025년 6월 30일 장 마감 기준 총 발행주식의 4.5%에 해당합니다. 제출서에는 해당 주식이 Point72 Asset Management가 운용하는 투자펀드에 속한다고 기재되어 있으며, Point72 Capital Advisors, Inc.는 Point72 Asset Management의 제너럴 파트너이고 코헨 씨가 두 법인을 통제한다고 명시되어 있습니다. 각 보고자는 단독 의결권 0단독 처분권 0을 보고했으며, 보고된 모든 권한은 공동 권한으로 표기되어 있습니다. 이 제출은 섹션 13의 목적상 실질적 소유권의 인정으로 해석되어서는 안 된다고 명시합니다.

Dianthus Therapeutics, Inc. - Le Schedule 13G/A indique que des entités liées à Point72 et Steven A. Cohen détiennent conjointement le pouvoir de vote et de disposition sur 1 445 825 actions ordinaires de Dianthus, soit 4,5 % de la catégorie à la clôture des marchés le 30 juin 2025. Le dépôt précise que les actions sont détenues par un fonds d’investissement géré par Point72 Asset Management ; Point72 Capital Advisors, Inc. est le partenaire général de Point72 Asset Management et M. Cohen contrôle les deux entités. Chaque déclarant signale 0 pouvoir de vote exclusif et 0 pouvoir de disposition exclusif, tous les pouvoirs étant déclarés comme partagés. Il est précisé que cette déclaration ne doit pas être interprétée comme une reconnaissance d’une propriété bénéficiaire au sens de la Section 13.

Dianthus Therapeutics, Inc. - In der Schedule 13G/A wird berichtet, dass Point72-nahe Einheiten und Steven A. Cohen zusammen die Stimm- und Verfügungsgewalt über 1.445.825 Aktien der Dianthus-Stammaktien innehaben, was zum Börsenschluss am 30. Juni 2025 4,5 % der Klasse entspricht. Die Einreichung gibt an, dass die Aktien von einem von Point72 Asset Management verwalteten Investmentfonds gehalten werden; Point72 Capital Advisors, Inc. ist der Generalpartner von Point72 Asset Management und Herr Cohen übt Kontrolle über beide Einheiten aus. Jeder Meldende gibt 0 alleinige Stimmrechte und 0 alleinige Verfügungsrechte an; alle gemeldeten Rechte sind als gemeinsam ausgewiesen. Es wird klargestellt, dass die Meldung nicht als Anerkennung einer wirtschaftlichen Eigentümerschaft im Sinne von Abschnitt 13 zu verstehen ist.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025

FAQ

How many Dianthus (DNTH) shares do Point72 and Steven A. Cohen report?

They report shared voting and dispositive power over 1,445,825 shares, equal to 4.5% of the class as of June 30, 2025.

Does the Schedule 13G/A indicate Point72 seeks control of Dianthus (DNTH)?

No. The filing includes a certification stating the securities were not acquired to change or influence control and were not acquired in connection with such a transaction.

What voting and dispositive powers are reported by the filers?

Each reporting person reports 0 sole voting and 0 sole dispositive power, and 1,445,825 shared voting and 1,445,825 shared dispositive power.

Which Point72 entities are named in the filing for DNTH?

The filing names Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. and lists Steven A. Cohen as a reporting person.

As of what date are the reported holdings for DNTH effective?

The holdings are reported as of the close of business on June 30, 2025.
Dianthus Therapeutics Inc

NASDAQ:DNTH

DNTH Rankings

DNTH Latest News

DNTH Latest SEC Filings

DNTH Stock Data

667.59M
29.66M
7.87%
119.91%
18.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK